Shares of medical imaging technology firm Feedback plc (LON: FDBK) are climbing on Wednesday after the company announced it had been awarded a one year contract with the Royal Berkshire NHS Foundation Trust.
Feedback’s share price is currently trading at 1.3p, up 4% from Tuesday’s close after initially climbing to 1.50p per share.
The contract is worth £84,000 and is for Bleepa, Feedback’s flagship clinical communications platform.
The company said the Trust is keen to evaluate Bleepa as part of its broader communication strategy and is a frontrunner in recognising the need to transition away from unregulated platforms such as WhatsApp for clinical communication.
Feedback will work with the Trust to enhance the Virtual Multi-Disciplinary Meetings module and evaluate the product's referral module, linking it to the existing workflow for clinical, intra-Trust referral pathways embedded in the Trust's Electronic Patient Record.
The Trust will also have access to the Photocapture feature, which Feedback feels will enable Bleepa to be used for a broader range of services outside of this contract, such as dermatology services, community nursing and diabetic wound management, allowing Bleepa to reach a wider clinical audience.
Should you invest in Feedback plc shares?
Feedback plc shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Feedback shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies